SIGN UP FOR THE LIFEMAG BRIEF

Receive our top articles each week direct to your inbox

In the News

First precision medicine trial in cancer prevention identifies molecular-based chemoprevention strategy

Published on 12th Nov 2015

Published on 12th November 2015

A team of scientists, led by researchers at The University of Texas MD Anderson Cancer Center and University of California, San Diego Moores Cancer Center, report that a genetic biomarker called loss of heterozygosity or LOH is able to predict which patients with premalignant mouth lesions are at highest risk of developing oral cancer.

Read more @ eCancerNews